Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

OGT Launches Cytocell FISH Probes for Glial Tumours

publication date: Jun 9, 2016
author/source: Oxford Gene Technology

Cost-effective, ready-to-use kit enables reliable co-deletion investigations

CytocellOxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours. 

Co-deletion of the 1p36.32 and 19q13.33 regions are frequently reported in many classes of gliomas.1,2 Moreover, the presence of a 1p and 19q co-deletion is a strong prognostic factor, which is often associated with improved outcome and responsiveness to therapy in stage II and stage III gliomas.3 Presenting the gold standard of co-deletion detection, FISH is also central in the move towards replacing morphological grading with molecular analysis — providing the molecular insights to overcome the variable relationship between histological type and clinical outcome.

Created specifically for the investigation of co-deletion status in glial tumour specimens, the new CE-IVD labelled Cytocell Aquarius 1p36/1q25 and 19q13/19p13 Deletion Probe Kit consistently delivers bright, specific signals with minimal background. By enabling clear and accurate scoring, the need for repeat testing is minimised, saving both time and resources. Ease of use has also been prioritised, with the convenience of ready-to-use pre-mixed probes saving aliquoting time, while also minimising potential errors. The cost-effective, quality-assured kit brings confidence to glioma investigations, with optimisation for FFPE samples enhanced when used alongside the Cytocell Tissue Pretreatment Kit.  

The Head of Cancer Cytogenetics at the Northern Genetics Service in Newcastle, Gavin Cuthbert FRCPath, who is currently in the process of completely transitioning to Cytocell probes, commented: “Accurately detecting co-deletion status is vital to our glioma investigations, and we have been consistently impressed with the quality and reproducibility of results using the new Cytocell kit — not to mention the support offered by OGT’s customer service. We now have a cost-effective test we can rely on, that is also easy to use and interpret.”

Senior Product Manager for Pathology at OGT, Steve Chatters explained: “More laboratories are realising the importance of FISH-based co-deletion analysis for glioma investigations, and our new kit is set to further drive this trend. This builds upon OGT’s existing cancer FISH portfolio, providing confident diagnoses to aid in the fight against cancer.”

more about oxford gene technology

more news from oxford gene technology




If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.